Literature DB >> 31135929

IMPACT OF PELVIC AND RAD-BOARD LEAD SHIELDS ON OPERATOR AND PATIENT RADIATION DOSE IN TRANS-RADIAL CORONARY PROCEDURES.

Aida Khaleghi Fard1,2, Amir Hossein Mohammad Alian3, Leili Pourafkari4,5, Morteza Ghojazadeh6, Ali Tarighatnia1,2,3, Alireza Farajollahi2,7.   

Abstract

BACKGROUND: Trans-radial approach for cardiac catheterisation procedures has long been associated with high operator and patient radiation dose. The aim of the present study was to determine the effect of pelvic and radial shields on decreasing coronary procedure radiation doses.
METHODS: A total of 418 patients randomly underwent diagnostic and therapeutic cardiac procedures with and without the pelvic and rad-board lead shields during the procedures. The operator and patient doses were then determined by means of a personal dosimeter and dose area product (DAP), respectively.
RESULTS: The shields decreased the operator radiation dose by 40% in coronary angiography (CA) and by 45% during angioplasty (PCI). These results were achieved at the cost of increased patient radiation dose.
CONCLUSION: Pelvic lead shields combined with rad-board shields are highly effective in reducing operator radiation dose in trans-radial approach, but it is only achieved at the cost of increased patient DAP.
© The Author(s) 2019. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Year:  2019        PMID: 31135929     DOI: 10.1093/rpd/ncz147

Source DB:  PubMed          Journal:  Radiat Prot Dosimetry        ISSN: 0144-8420            Impact factor:   0.972


  2 in total

1.  Can leaded glasses protect the eye lens in patients undergoing neck computed tomography?

Authors:  Reza Abedi; Naser Ghaemian; Ali Shabestani Monfared; Mohammad Kiapour; Razzagh Abedi-Firouzjah; Fatemeh Niksirat; Alaba Tolulope Agbele; Kourosh Ebrahimnejad Gorji
Journal:  J Clin Transl Res       Date:  2021-07-16

2.  Cardiac catheterization real-time dynamic radiation dose measurement to estimate lifetime attributable risk of cancer.

Authors:  Chun-Yuan Tu; Chung-Jung Lin; Bang-Hung Yang; Jay Wu; Tung-Hsin Wu
Journal:  PLoS One       Date:  2020-06-16       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.